Austria will introduce a full lockdown that could last for three weeks on Monday in an attempt to tackle a new wave of Covid-19 infections. The government has also ordered the entire population to get vaccinated from February 1.
On Friday, conservative Chancellor Alexander Schallenberg told a news conference that a complete lockdown of the nation would begin on Monday and last for an initial 10 days.
He stated that the restrictions could be extended if infection rates did not start to fall, but he insisted the lockdown would not exceed 20 days.
The measures concern the entire Austrian population. The government has already imposed a partial lockdown on the unvaccinated in an effort to reduce hospitalization rates amid a surge in Covid-19 cases.
When the full lockdown ends, restrictions will remain in place for the unvaccinated.
Schallenberg’s announcement came after a meeting of nine state governors, two of whom had already vowed to introduce full lockdowns in their regions on Monday, in the western province of Tyrol.
The chancellor also announced that vaccinations would be mandatory from February 1. “We haven’t been able to convince enough people to vaccinate. For too long, I and others have assumed that you can convince people to get vaccinated,” he added, giving his rationale for the mandate.
Schallenberg said he lamented the political forces, radical opposition, and fake news fighting against vaccination.
Austria has one of the lowest vaccination rates in western Europe, with only 65% inoculated against the deadly virus according to data from Johns Hopkins university.
Infection rates are almost among the highest on the continent. The seven-day incidence rate stands at 971.5 per 100,000 people.
Think your friends would be interested? Share this story!
Pfizer has agreed to grant a royalty-free license to sell its anti-coronavirus pill in nearly 100 developing countries around the world.
Under the agreement signed with the Medicines Patent Pool (MPP), a UN-backed public health organization, Pfizer will not receive royalties on the sales of its promising antiviral pill in 95 poorer countries, including the states of Sub-Saharan Africa. The measure allows MPP to grant sub-licenses to “qualified” generic medicine manufacturers in each country.
The countries covered by the deal comprise around 53% of the world’s population, Pfizer said. “We believe oral antiviral treatments can play a vital role in reducing the severity of Covid-19 infections, decreasing the strain on our healthcare systems and saving lives,” Pfizer CEO Albert Bourla said.
We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs.
During its phase-two/three trial, the drug PF-07321332, trademarked as Paxlovid, reduced the risk of hospitalization or death by 89% in Covid-19 patients who took it within three days of symptom onset. The drug is administered in combination with low-dose ritonavir, a medication used to treat HIV/AIDS.
The UN and the World Health Organization (WHO) have long been urging companies to make vaccines and other forms of Covid-19 treatment accessible and affordable for developing countries.
Think your friends would be interested? Share this story!
An exoplanet some 70% the mass of Jupiter and about 1.4 times its size has been discovered by astronomers at India’s Physical Research Laboratory (PRL). The behemoth is 752 light years away from Earth, and has an incredible orbit.
The new discovery was revealed by the Indian Space Research Organization on Tuesday in a statement saying the country’s PRL Advanced Radial-velocity Abu-sky Search (PARAS) had measured the movements of the newly-discovered exoplanet between December 2020 and March 2021.
The planet, named either HD 82139 or TOI 1789 depending on which cataloguing method is used, is ultra-hot – with a surface temperature up to 2,000 degrees Kelvin.
India’s PRL Advanced Radial-velocity Abu-sky Search (PARAS), an optical fiber-fed spectrograph, observed t he exoplanet and its movements from the Mt. Abu Observatory, according to the space agency. Not only is the planet ultra-hot, but it is also one of the closest to an orbiting star yet discovered.
The measurements obtained via PARAS were confirmed by Germany’s TCES spectrograph in April, and further verified by independent photometric observations from the PRL’s 43cm telescope, also located at Mt. Abu.
The exoplanet has an unusually quick orbit – a mere 3.2 days. The pace indicates that its distance from its host star is one-tenth the distance between Mercury and the Sun. This makes the exoplanet one of fewer than 10 such solar systems discovered thus far. Given the closeness to its host star – an aging orb 1.5 times the mass of the Sun – the new planet is also one of the lowest density planets yet discovered.
Planets so close to their host stars, with a distance less than 0.1 AU and masses between 0.25 to several times the mass of Jupiter, are known as “hot-Jupiters.”
The Indian space agency hailed the detection of the new planet as an opportunity to “enhance our understanding of various mechanisms responsible for inflation in hot-Jupiters and the formation and evolution of planetary systems around evolving and aging stars.” It is the second planet to be discovered by PARAS, with a previous discovery taking place in 2018.
France shouldn’t remain silent on Julian Assange, leftist leader Jean-Luc Melenchon has said, after the imprisoned WikiLeaks co-founder’s father suggested that Paris could offer asylum to his son.
The life of Assange – who is being held in solitary confinement at London’s Belmarsh maximum security prison while a British court considers an extradition request by the US – is under threat, Melenchon wrote on Twitter on Tuesday.
“For years, we’ve been calling for France to accept him,” the head of the leftist La France Insoumise (France Unbowed) party said, insisting that “France shouldn’t remain silent.”
The statement by Melenchon, who won 19.6% of the ballot in the first round of the French presidential election in 2017, follows a visit by Assange’s father, John Shipton, to the Whistleblower Meeting in Paris on Monday.
During the event, Shipton told Sputnik news agency that it would be “an honorable thing” for the French government to grant his son asylum.
“I feel that France hasn’t attacked Julian over the last 12 years and consequently France is free to act in return for the information that WikiLeaks and Julian brought to France,” he said, referring to the website’s revelations of the US intelligence agencies spying on French presidents and hacking into local banks.
🔴 John #Shipton : «La France n’a pas attaqué #Julian pendant les dernières années difficiles, donc la France est libre d’agir en échange des informations que #WikiLeaks et Julian ont apportées à la France. Ce serait honorable pour la #France d’offrir [l’asile] à Julian #Assange» pic.twitter.com/ceZ7qTARua
Several dozen French lawmakers have also recently called upon Paris to take Assange in, with the Australian-born publisher’s legal team saying last year that their client was hoping to find asylum on French soil.
Assange could face up to 175 years behind bars if he’s extradited to the US, where he’s wanted on espionage charges over the release by WikiLeaks of classified documents on Iraq, Afghanistan, Guantanamo Bay, and others.
He was placed in Belmarsh in April 2019 over breach of bail, after being holed up in the Ecuadorian Embassy in London for seven years.
The publisher had been fleeing an arrest warrant issued over sexual assault allegations which he has always denied, and which failed to result in any actual charges due to lack of evidence.
Assange’s supporters insist that he has actually been persecuted over his legitimate journalistic activities and revealing the truth to the public.
The UK High Court is expected to rule on the appeal by the US against a lower court decision to bar the WikiLeaks co-founder’s extradition to America due to the 50-year-old’s poor health condition and risk of suicide.
Assange’s team will then be able to challenge the ruling in the Supreme Court if it’s not favorable.
Think your friends would be interested? Share this story!
As infections are rising again, scientists all around the world are rushing to fight the danger, offering a choice of new treatments and unusual variants of vaccines.
Levels of contagion are setting new records, hospitals are overwhelmed, governments are starting to introduce lockdowns, and not only for unvaccinated people – the picture of the fight against Covid-19 looks quite disappointing. However, there’s still a place for good news: Research teams report positive results while trialling new medicines and vaccine types.
Nasal vaccines
Vaccination will remain one of the most effective tools against Covid-19. As Professor David Dockrell, from the Center for Inflammation Research of the University of Edinburgh, told RT, “vaccines will continue to be a central part of how we control the virus.”
“If we can dampen down the number of infections, and the severity of infections, and also the extent to which the virus can replicate in people when they become infected, then we are slowing down the ability of the virus to change and to mutate,” he explains.
So I think the vaccines still will be a very important part of the preventive strategy. It’s vital that they are available to all the world’s population, irrespective of where people live, and the wealth of the country in which they live.
However, vaccination doesn’t always mean you have to get an injection. For instance, several intranasal Covid-19 vaccines are currently being developed. As the virus gets into the body through the nose, a nasal spray or drops are aimed to produce mucosal immune response and prevent it from getting into the lungs.
In India, a vaccine of this type is already completing Phase 2 of clinical trials. In Russia, a nasal vaccine is undergoing a clinical trial on volunteers. In Thailand, a home-developed product is expected to be trialed on humans next spring. In the US, Universities of Houston and Stanford recently reported good results of their experiments carried out on mice.
Intranasal vaccines can have several potential benefits compared to inoculation.
“They would be easier to use, because they can be self-administered. They wouldn’t need a nurse or clinical settings,” Swedish professor emeritus of epidemiology Marcello Ferrada de Noli explained to RT. As a result, he says, there’s hope that fewer people will be reluctant to be immunized. Not so many of us find it pleasant to get a jab – and after all, there are those who are just afraid of needles. Also, it would be much easier to vaccinate children with nasal substances.
However, what concerns Prof. de Noli the most is the duration of the effect of a vaccine of this type. Still, scientists can’t say for sure whether a nasal substance may completely replace a shot. According to Alexander Gintsburg, the head of Moscow’s Gamaleya Center biomedical research institute, which created the Sputnik V vaccine, the nasal version they are working on would serve for an additional protection against the virus, but would not replace the injections.
Chew the virus away?
A nasal vaccine is not the only one being developed. In summer, it was revealed that Russian Defense Ministry scientists were creating a ‘chewing gum’ vaccine, also targeting the mucosal immune response. Meanwhile, a UK firm announced this month that it would conduct a human trial of a skin patch that uses T-cells to confront the virus. Developers hope it would offer longer-lasting immunity than the existing vaccines. Work on a similar project is being done in the University of Queensland, Australia.
While it all looks so promising, Prof. de Noli warns that it would still take a lot of time until these products become available to the public. “I think that discoveries in this field are a very good thing. But if we say ‘We discovered a new type of vaccine’, people will say ‘Aha, so I’m going to wait’. But we need to vaccinate people now,” he points out.
Improving Covid treatment
Vaccines are not a silver bullet, unfortunately, given the not-so-high level of global immunization and the constantly emerging new strains of the virus. “People might get infected despite having had a vaccine, but I still think the vaccine strategy is going to be central to how we manage this kind of virus going forward,” Prof. Dockrell says. “But we will have other strategies that will be very important. We will have other elements. When we put them all together, it gives us the best opportunity that people can live with coronaviruses, and hopefully, the mortality can be limited to much lower extense than what we’ve sadly seen in the last eighteen months.”
Monoclonal antibodies will be central to the ongoing vaccine strategy, Prof. Dockrell explains. These are the antibodies similar to those the body uses to fight the virus. They are produced in labs and given via infusion or injection to boost the patient’s response against certain diseases. Monoclonal antibody treatment is used for people under a high risk of developing severe infection (including older patients 65+ years old or those with chronic medical conditions). It’s already being used in the US, following last year’s FDA approval. Earlier in November, the European Medicines agency recommended authorizing two monoclonal antibody medicines.
In October, UK’s AstraZeneca reported positive results of a Phase 3 study of its antibody combination, which, according to developers, is highly effective in both prevention and treatment of coronavirus.
Researchers are also working on a possibility to save Covid-infected patients from the so-called ‘cytokine storm’ – a situation when the immune system reacts so intensely that kills not only the virus, but the whole organism itself. A drug to ‘calm the storm’ was registered in Russia this year, and it’s already being used on patients.
Another way to fight Covid-19 is to use antiviral drugs. When the pandemic started, medics had to use something already existing (like anti-influenza Favipiravir) or something being authorized for emergency use (like remdesivir). Now, more than a year on, the work to create a special drug to specifically cure Covid-19 is giving its results. This month, Russia registered its first injectable anti-Covid medicine. A bit earlier, the UK became the first country to approve an antiviral pill produced by the US-based companies Merck and Ridgeback Biotherapeutics. Another American firm, Pfizer, got positive results from trials of its drug of the same kind. Both firms hope that with a drug in the form of a pill it would be easier to treat people at home.
Appreciating all the efforts on the field of developing anti-Covid treatment, Prof. de Noli points out that still, the key issue now is to reduce the spreading of the virus. “The new medicines are developed for people who already got the disease,” he says.
But we need to prevent people from getting the infection, not let them get infected because we have some new medicine that can cure them.
The same idea is echoed by scientists all over the world quoted in plenty of articles dedicated to the medical gains: it’s great to have the treatment, but none of the drugs may substitute vaccination, as first and foremost, humanity has to adopt preventive measures and stop the pandemic.
Just three days after restrictions were announced for unvaccinated Austrians, a provincial governor is pressing for a nationwide lockdown of all residents as Covid-19 infections continue to hit record highs.
“If no national lockdown is ordered tomorrow, there will definitely have to be a lockdown of several weeks in Upper Austria, together with our neighboring province Salzburg as of next week,” Upper Austria Governor Thomas Stelzer told lawmakers on Thursday.
That will mean at least two of Austria’s nine provinces will be in full lockdown mode just days after the nation created a two-tier society by locking down approximately two million unvaccinated Austrians.
“We must raise the vaccination rate. It is shamefully low,” Chancellor Alexander Schallenberg said on Sunday, announcing that unvaccinated residents would only be allowed to leave their homes for “essential” purposes, such as to buy groceries or go to a doctor’s office.
Police are now doing random checks for proof of vaccination on Austrian streets. Those unvaccinated residents who are found to be in violation of the lockdown order face steep fines of up to €500. Those who refuse to go through a vaccination status check will have to pay about three times as much.
Stelzer and other Austrian governors are scheduled to meet with Schallenberg and Health Minister Wolfgang Mueckstein on Friday, when a full lockdown will likely be considered.
New Covid-19 cases in the country passed the 15,000 mark for the first time on Thursday, far surpassing 2020’s daily high of 9,586, set when no vaccines were available. Upper Austria and Salzburg have been hit the hardest, putting hospitals at risk of bed shortages. With some 66% of its population fully vaccinated, Austria lags behind other Western European countries in terms of the Covid-19 vaccination rate.
While Austria is the first to impose a lockdown on the unvaccinated, other EU countries – including Slovakia, the Czech Republic and Greece – have imposed increasingly tight restrictions on people who haven’t accepted a Covid vaccine.
Think your friends would be interested? Share this story!
